

S:gte 04/28/04 5759-67433-01 273931

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: O'Hare et al.

Application No. 10/727,109

Filed: December 2, 2003

Confirmation No. 4401

For: DELIVERY OF SUBSTANCES TO CELLS

Examiner:

Art Unit: 1632

Attorney Reference No. 5759-67433-01

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP MISSING PARTS, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Agent  
for Applicant(s)

Date Mailed April 28, 2004

MAIL STOP MISSING PARTS  
COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT  
FOR CONTINUING APPLICATIONS

Listed on the accompanying form PTO-1449 are several English-language documents. Applicants respectfully request that such documents be listed as references cited on the issued patent.

The present application relies upon U.S. Patent Application No. 09/522,278, which was filed March 9, 2000, for an earlier filing date under 35 U.S.C. § 120. Furthermore, documents listed on the accompanying form PTO-1449 were disclosed to or cited by the Patent Office in the earlier U.S. application.

Copies of the documents listed on the accompanying form PTO-1449 that were cited by applicants in the earlier application need not be sent to the Patent Office pursuant to 37 C.F.R. § 1.98. However, applicants will furnish the Patent Office with such copies upon request.


Please charge any additional fees that may be required in connection with filing this Information Disclosure Statement, or credit any overpayment, to Deposit Account No. 02-4550. A duplicate copy of this sheet is enclosed.

The filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By



Susan Alpert Siegel, Ph.D.  
Registration No. 43,121

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Facsimile: (503) 228-9446

cc: Docketing



# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

Attorney Docket Number	5759-67433-01
Application Number	10/727,109
Filing Date	December 2, 2003
First Named Inventor	O'Hare
Art Unit	1632
Examiner Name	Not yet assigned

## **U.S. PATENT DOCUMENTS**

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		5,935,777	10 Aug 1999	Moyer et al.
		6,025,140	Feb 2000	Langel et al.
		6,034,135	7 March 2000	Schwartz et al.
		6,184,038	6 Feb 2001	O'Hare et al.
		6,376,248	April 2000	Hawley-Nelson et al.

## **FOREIGN PATENT DOCUMENTS**

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		WIPO	WO 97/05265	13 Feb. 1997	O'Hare et al.
		WIPO	WO 97/24453	10 July 1997	Rosenberg
		WIPO	WO 98/32866	30 July 1998	O'Hare et al.

## **OTHER DOCUMENTS**

Examiner's Initials*	Cite No. (optional)	
		Branch, A., <i>TIBS</i> 23:45-50, 1998.
		Crooke, S., editor, <u>Antisense Research and Application</u> , Springer-Verlag, Berlin, Ch. 1, 1-50, 1998.
		Phelan et al., <i>Nature Biotechnology</i> , 16:440-443, 1998.

EXAMINER  
SIGNATURE:

DATE  
CONSIDERED:

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.